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Abstract 24 
Introduction: Diabetic nephropathy (DN) is the leading cause of kidney failure in the world. To 25 
understand important mechanisms underlying this condition, and to develop new therapies, good 26 
animal models are required. In mouse models of type-1 diabetes, the DBA/2J strain has been 27 
shown to be more susceptible to develop kidney disease than other common strains. We 28 
hypothesized this would also be the case in type-2 diabetes. Methods: We studied db/db and wt 29 
DBA/2J mice and compared these with the db/db BLKS/J mouse, which is currently the most 30 
widely used type-2 DN model. Mice were analyzed from age 6 to 12 weeks for systemic insulin 31 
resistance, albuminuria and glomerular histopathological and ultra-structural changes. Results: 32 
Body weight and non-fasted blood glucose were increased by 8-weeks in both genders, while 33 
systemic insulin resistance commenced by 6-weeks in female and 8-weeks in male db/db DBA/2J 34 
mice. The urinary albumin-to-creatinine ratio (ACR) was closely linked to systemic insulin 35 
resistance in both sexes and was increased ~50-fold by 12 weeks age in the db/db DBA/2J cohort. 36 
Glomerulosclerosis, foot process effacement and glomerular basement membrane thickening 37 
were observed at 12-weeks of age in db/db DBA/2J mice. Compared to db/db BLKS/J mice, db/db 38 
DBA/2J mice had significantly increased levels of urinary ACR, but similar glomerular 39 
histopathological and ultrastructural changes. Conclusion: The db/db DBA/2J mouse is a robust 40 
model of early stage albuminuric DN and its levels of albuminuria correlate closely with systemic 41 
insulin resistance. This mouse model will be helpful in defining early mechanisms of DN and 42 
ultimately the development of novel therapies.  43 
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Introduction 44 
Diabetic nephropathy (DN) is the leading cause of kidney failure in the world with over half of 45 
patients in the United States entering the end stage renal failure (ESRF) program for this reason. It 46 
is increasing at alarming rates throughout both the developed and developing worlds 47 
predominantly due to the global epidemic increase in type-2 diabetes (33) caused by sedentary 48 
lifestyles, diet and obesity (16). DN generally has a well-defined natural history and initially affects 49 
the glomerulus manifesting as hyperfiltration and microalbuminuria (30-300 mg albumin/24 50 
hours) before progressing to macroalbuminuria (more than 300mg/albumin/ 24 hours). 51 
Macroalbuminuria usually heralds the start of declining glomerular filtration and associated 52 
tubulointerstitial fibrosis. The best current biomarker for kidney involvement in DN is the presence 53 
of micro or macroalbuminuria. These may be helpful in identifying affected kidneys and allow 54 
therapies to be started early before established fibrotic kidney disease is present. It is now clear 55 
that systemic insulin resistance is closely linked to DN progression in both type-1 (25) and type-2 56 
DN (12) so finding models that mimic this would be beneficial in understanding mechanisms and 57 
ultimately identifying therapeutic targets to stop early DN from progressing. To understand the 58 
mechanisms underlying DN it is vital to have good cellular and animal models of DN, but these are 59 
currently suboptimal.  60 
In diabetic patients, multiple genetic factors modulate the risk of developing DN (11, 26). 61 
Similarly in mice, the susceptibility to kidney injury is influenced by the inbred mouse strain used 62 
as have been illustrated in models of type-1 diabetes. At one extreme, the C57BL/6J strain is 63 
resistant to DN in the STZ-induced and the Ins2+/C96Y (Akita) models of diabetes as diabetic mice 64 
develop only subtle albuminuria with slow advancement of mesangial matrix expansion (13, 14). 65 
At the other extreme, the DBA/2J strain displays enhanced susceptible to DN and develop 66 
exaggerated urinary albumin excretion compared with other common inbred mouse strains 67 
including C57BL/6J, A/J and Sv129 in the STZ-induced (13, 28) and the Akita (5, 14) models.  68 
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The genetic background also influences the susceptibility to DN in the db/db mouse model, 69 
where an autosomal recessive mutation in the Lepr gene (i.e. the diabetogenic db allele) renders 70 
mice obese, insulin resistant and diabetic (7). The phenotypical manifestations of the db allele 71 
were first described in the C57BLKS/J (BLKS/J) strain (17), which is a genetic composite between 72 
the DN resistant C57BL/6J and DN susceptible DBA/2J strains in addition to alleles from at least 73 
three other strains including SV129 (22). The db/db BLKS/J mouse is susceptible to DN and 74 
develops significant albuminuria by 8 weeks of age (2, 6, 23, 30) along with histopathological 75 
features of early DN by 12-weeks of age including glomerular enlargement (21, 23) and 76 
glomerulosclerosis (6, 21, 23). Despite having more than 70% of its genome derived from the DN 77 
resistant C57BL/6J strain, the db/db BLKS/J mouse constitutes a robust model of the early changes 78 
in human DN (1) and DBA/2J-derived genetic components may be responsible for the susceptibility 79 
to DN in this strain. Although the db allele has been introduced in the DBA/2J strain (19), the 80 
susceptibility to albuminuric kidney disease and development of DN in the db/db DBA/2J mouse 81 
remains to be explored in detail. 82 
Here we describe the development of early DN in the db/db DBA/2J mouse to investigate 83 
the influence of genetic background on the susceptibility to kidney injury during the transition 84 
from prediabetes to diabetes in the db/db mouse model. We hypothesize that the DBA/2J strain 85 
display augmented albuminuria as well as histopathological and ultrastructural changes compared 86 
to the commonly used BLKS/J strain. Using female and male db/db DBA/2J mice alongside age- 87 
and gender-matched lean controls, we characterized the development of metabolic parameters 88 
(i.e. body weight, blood glucose and systemic insulin sensitivity) and the development of kidney 89 
injury (i.e. urinary albumin-to-creatinine ratio, glomerulosclerosis score and ultrastructural 90 
features). We investigated the effects of genetic background on DN by comparing our findings to a 91 
cohort of db/db BLKS/J mice. 92 
 93 
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Materials & Methods 94 
Mouse breeding and housing 95 
Heterozygous db/wt DBA/2J (D2.BKS(D)-Leprdb/J) breeders were purchased from The Jackson 96 
Laboratory (Bar Harbor, ME, US) to breed female and male db/db mice and lean wild type 97 
offspring in house. To obtain adequate numbers of lean control mice, both db/wt and wt/wt mice 98 
were included in the experiment - hereinafter referred to as wt mice. Data on outcome of 99 
breeding are presented in Table 1. Male db/db and heterozygous db/wt BLKS/J (BKS.Cg-Dock7m 100 
+/+ Leprdb/J) mice were purchased from Charles River (Calco, Italy). 101 
All mice were housed in a 12/12 h light/dark cycle with free access to standard chow 102 
(EURodent Diet 22%, percentage of energy: protein 25.9%, fat 9.3%, carbohydrate 64.8%; LabDiet, 103 
St. Louis, MO, US) and water. All animal procedures were carried out according to the Guidance of 104 
the Operation of the Animals (Scientific Procedures) Act 1986 and all protocols were approved by 105 
the Home Office (London, UK).     106 
 107 
Characterization of metabolic parameters 108 
To characterize the early metabolic phenotype of the db/db model, a total of 24 db/db (12 109 
females, 12 males) and 15 wt (8 females, 7 males) DBA/2J mice were kept from 6 and up to 12 110 
weeks of age, whereas 6 male db/db and 6 wt BLKS/J mice were kept from 8 to 12 weeks of age. 111 
Body weight and non-fasted blood glucose were measured biweekly. Blood glucose was measured 112 
in tail vein blood using an Accu-Chek Aviva Nano portable glucometer (Roche, Indianapolis, IN, 113 
US). 114 
Systemic insulin sensitivity was assessed by insulin tolerance tests (ITT) at 6, 8 and 12 weeks 115 
in DBA/2J mice, and at 8 and 12 weeks in BLKS/J mice. Briefly, mice were fasted for 6 h with free 116 
access to water. Human insulin (Novo Nordisk, Måløv, Denmark) was injected intraperitoneally 117 
(i.p.) at a dose of 0.20 IU/kg in females and 0.50 IU/kg in males, respectively. Blood glucose was 118 
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measured in tail vein blood before (T=0 min) and 15, 30, 45, 60 and 90 min after insulin injection 119 
using an Accu-Chek Aviva Nano portable glucometer. The applied doses of insulin were empirically 120 
determined prior to ITTs as the dose required to reduce blood glucose by 20-40% from baseline 15 121 
min after i.p. insulin injection in 8 week old wt DBA/2J mice.  122 
By 12 weeks of age, mice were fasted for 6 h with free access to water and euthanized by an 123 
i.p. injection of pentobarbital (200 mg/kg). Blood was collected by cardiac puncture, transferred to 124 
heparinized tube, spun and plasma store at -80°C. Plasma insulin and IGF-1 were quantified using 125 
the Ultrasensitive Mouse Insulin ELISA kit and Mouse IGF-1 ELISA kit (both Crystal Chem, both 126 
Crystal Chem, Downers Grove, IL, US), respectively, according to manufacturer’s instructions. 127 
Plasma creatinine was measured using the creatinine enzymatic assay as previously described (18). 128 
Finally, kidneys were dissected and either snap-frozen in liquid nitrogen or fixed for histological 129 
and ultrastructural evaluation as described below. 130 
 131 
Urine collection and urinary albumin excretion 132 
To assess urinary albumin excretion, spot urine samples were collected biweekly and stored at -133 
20°C. The urinary albumin-to-creatinine ratio (ACR) was quantified using the Mouse Albumin ELISA 134 
Quantification Set (Bethyl Laboratories, Montgomery, TX) and the Creatinine Companion kit 135 
(Exocell, Philadelphia, PA, US) according to manufacturer’s instructions. Urinary albumin excretion 136 
was also assessed by gel electrophoresis. Briefly, urine samples (5 µl per well) and a BSA control 137 
(Sigma-Aldrich, Gillingham, UK) of 10 µg per well were separated in 12% Mini-PROTEAN TGX gels 138 
and proteins visualized by coomassie stain using Bio-Safe Coomassie G-250 Stain (both Bio-Rad, 139 
Hemel Hempstead, UK). 140 
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 141 
Glomerular histopathology and ultrastructure 142 
For histopathological evaluation, dissected kidneys were fixed in 4% formalin at 4°C, dehydrated, 143 
embedded in paraffin and cut at 3 µm before staining with Periodic acid–Schiff (PAS) and Masson’s 144 
Trichrome (TRI) stains using kits (both Sigma-Aldrich) according to manufacturer’s instructions. 145 
Glomerulosclerosis was scored semi-quantitatively according to the percentage of the glomerular 146 
tuft occupied with PAS-positive and nuclei-free matrix. From each mouse, a minimum of 18 147 
glomeruli were scored according to a 5 point scale using the following criteria: 0) normal 148 
glomerulus; 1) up to 25% matrix area; 2) 25-50% matrix area; 3) 50-75% matrix area – focal; 4) 75-149 
100% matrix area – global.  150 
For immunofluorescence staining, frozen kidneys were cut at ~8 µm using a freezing 151 
microtome and sections blocked with 5% normal goat serum in 0.3% Triton X-100/PBS before 152 
incubation with primary antibodies against nephrin (Acris, Hereford, Germany) and collagen IV 153 
(Abcam, Cambridge, UK). All sections were incubated with Alexa Fluor® 405 and 488-conjugated 154 
secondary antibodies in 3% BSA, 0.3% Triton X-100/PBS and mounted with Vectashield mounting 155 
medium (Vector Laboratories, Peterborough, UK) before imaging using a Leica SP5II confocal laser 156 
scanning microscope attached to a Leica DMI 6000 inverted epifluorescence microscope with a 157 
63x oil immersion objective lens. 158 
For evaluation of glomerular ultrastructure including foot process effacement and 159 
glomerular basement membrane thickening, ~1 mm3 cubes from the renal cortex were fixed in 160 
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer at 4°C. Samples were post-fixed in 1% 161 
osmium tetroxide in 0.1M sodium cacodylate buffer (pH 7.4) and en bloc stained in 3% aqueous 162 
uranyl acetate followed by dehydrated through a graded series of alcohol. Samples were 163 
embedded in Epon Resin and thin-sectioned at 70 nm. Digital micrographs were taken on a FEI 164 
Tecnai Spirit T12 (120KV) Transmission Electron Microscope (TEM). 165 
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Statistical analyses 166 
Data were modelled and groups compared using linear mixed-effects models in R (version 3.2.1; 167 
open source software available at www.cran.r.project.org). Fixed effects (group, age, gender and 168 
strain) and random effects (mouse and litter) were included in the models as found appropriate. 169 
Longitudinal variables were analyzed as repeated measurements using the lme function to test for 170 
the effect of age and to compare groups, while variables that were independent of age and 171 
variables that were measured at one time-point only were analyzed using the lmer function. 172 
Model residuals and fitted values were tested for normality. In cases of non-normality, data were 173 
log10-transformed prior to modelling and group comparison. Linear correlation analyses were 174 
conducted in GraphPad Prism (version 6.05; GraphPad Software, La Jolla, CA). Unless stated 175 
otherwise, data are presented as means ± standard error of the mean (SEM). Resulting P values 176 
are evaluated at a 5% significance level.     177 
 178 
Results 179 
Metabolic phenotype of the db/db DBA/2J mouse 180 
Body weight and non-fasted blood glucose were monitored from 6-12 weeks of age in female and 181 
male db/db and wt DBA/2J mice to characterize the early development of obesity and 182 
hyperglycemia. The body weight was significantly higher in db/db vs wt females from 6 through 12 183 
weeks of age (all P<0.001, Fig. 1A) and reached a 96% increase by the end of the study period. 184 
Male db/db mice had increased body weight compared to wt mice at 8-12 weeks of age (P<0.001 185 
at 8 and 10 weeks, P<0.05 at 12 weeks) reaching a 37% increase by 10 weeks after which the 186 
db/db males experienced a significant drop in body weight through to 12 weeks of age (P<0.05).  187 
Non-fasted blood glucose was similar in all groups at 6-weeks of age but became significantly 188 
higher in db/db vs wt mice from 8 through to 12-weeks of age in both genders (all P<0.001, Fig. 189 
1B). Blood glucose did not increase significantly beyond 8-weeks in female and 10-weeks in male 190 
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db/db mice. Plasma insulin was measured only at 12 weeks of age and was significantly increased 191 
in female db/db vs wt mice (7.15 ± 0.64 vs 0.29 ± 0.03 ng/ml, P<0.001, Fig. 1C), while no significant 192 
difference was observed between male groups (2.25 ± 0.98 vs 1.36 ± 0.44 ng/ml).  193 
ITTs were conducted at 6, 8 and 12 weeks to assess systemic insulin resistance, which was 194 
quantified by the AUC from ITT curves in females (Fig. 2A) and males (Figs 2C). Systemic insulin 195 
resistance was significantly increased in female db/db vs wt mice by 6 weeks of age (P<0.01, Fig. 196 
2B) and by 8 weeks of age in males (P<0.001, Fig. 2D). In both genders, insulin resistance worsened 197 
significantly from 6 through to 12 weeks of age (both P<0.001).   198 
 199 
Albuminuria correlates with systemic insulin resistance in the db/db DBA/2J mouse 200 
The development of albuminuria was explored in db/db DBA/2J mice from 6 to 12 weeks of age 201 
and quantified by the urinary ACR. Female db/db mice had significantly higher urinary ACR 202 
compared to wt controls through 6-12 weeks of age (P<0.01 by 6 weeks, P<0.001 by 8-12 weeks, 203 
Fig. 3A), while ACR was increased from 8 through to 12 weeks of age in male db/db vs wt mice (all 204 
P<0.001, Fig. 3B). This correlates with the onset of systemic insulin resistance as presented in 205 
figure 2B and 2D, respectively. The statistical analyses showed no significant effect of gender on 206 
the ACR fold change between db/db and wt controls, but a significant effect of age was observed 207 
as ACR fold change increased from 5-fold by 6 weeks to 50-fold by 12 weeks of age (P<0.001, Fig. 208 
3C). To explore the association between albuminuria and metabolic parameters, we performed 209 
correlation analyses between urinary ACR and body weight, blood glucose and systemic insulin 210 
resistance, respectively. We observed significant positive correlations between ACR and all three 211 
metabolic parameters in both female and male mice (all P<0.001, see R2 in Fig. 3D-F).   212 
  213 
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Glomerular histopathology and ultrastructure in the db/db DBA/2J mouse 214 
To evaluate the glomerular histopathological changes in the db/db DBA/2J mouse, kidney sections 215 
were PAS, TRI and collagen-IV stained. Representative micrographs from 12-week old db/db and 216 
wt DBA/2J mice are presented in Fig. 4A. PAS stained sections showed glomerulosclerosis in the 217 
db/db mice, but not controls, at high magnification (second row - arrowed). Evaluation of TRI 218 
stained sections revealed that glomerular fibrosis was present when studying high magnification 219 
TRI stained micrographs (fourth row - arrowed). Finally, we observed type IV collagen 220 
accumulation in db/db, but not wild-type glomeruli (bottom row). 221 
Semi-quantitative analysis was performed using glomerulosclerosis score (GS) in PAS stained 222 
kidney sections showed an increase in the percentage of glomeruli with GS ≥1 in db/db vs wt mice 223 
by 8 weeks of age (Fig. 4B). The mean GS was significantly increased in db/db vs wt DBA/2J mice at 224 
8 and 12 weeks of age (both P<0.001, Fig. 4C), whereas no significant worsening in GS was 225 
observed from 8 to 12 weeks in db/db DBA/2J mice. The mean GS correlated positively with 226 
urinary ACR in the DBA/2J cohort (P<0.001, R2=0.7686, Fig. 4D). 227 
Ultrastructural changes between 12-week old db/db and wild-type controls were evaluated 228 
by TEM and representative images are displayed in Fig. 5A (top row). Significant increases in 229 
podocyte foot process width (P<0.05, Fig. 5B) and glomerular basement membrane (GBM) 230 
thickness (P<0.001, Fig. 5C) were detected in db/db vs wt DBA/2J mice. 231 
 232 
Effects of genetic background on the metabolic phenotype in the db/db mouse model 233 
The metabolic phenotype of male db/db DBA/2J and BLKS/J mice was compared to explore the 234 
effects of genetic background on the phenotypical manifestation of the db allele. The body weight 235 
of db/db DBA/2J mice was 16-20% lower than db/db BLKS/J mice throughout the study period 236 
(P<0.001, Table 2). Unlike db/db DBA/2J mice, db/db BLKS/J males did not demonstrate any 237 
weight loss during the study period although their body weight was unchanged from 10 weeks of 238 
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age. Non-fasted blood glucose were significantly lower in db/db DBA/2J mice at 8 weeks (P<0.001, 239 
Table 2), but reached similar levels to that of db/db BLKS/J mice by 12 weeks age. Systemic insulin 240 
resistance was significantly lower in db/db DBA/2J vs BLKS/J males at 8 and 12 weeks of age 241 
(P<0.001 and P<0.05, respectively, Table 2). In wt mice, genetic background did not significantly 242 
affect the metabolic parameters presented in Table 2. Finally, comparisons of plasma insulin levels 243 
showed no significant differences between male DBA/2J and BLKS/J cohorts in either db/db 244 
(2.25±0.98 vs 4.64±2.45 ng/ml) or wt mice (1.36±0.44 vs 1.11±0.2 ng/ml). 245 
 246 
Effects of genetic background on kidney injury in the db/db mouse model 247 
To evaluate the effects of genetic background on the susceptibility to kidney injury, we compared 248 
albuminuria as well as renal structural and histopathological changes between male db/db DBA/2J 249 
and db/db BLKS/J mice. Qualitative analysis of urine samples by SDS-PAGE indicated increased 250 
urinary albumin concentrations in db/db DBA/2J vs db/db BLKS/J mice at 8 and 12 weeks of age 251 
(Fig. 6A). In addition, urinary ACR was significantly higher in db/db DBA/2J vs db/db BLKS/J mice 252 
(P<0.05, Fig. 6B) with ACR fold changes in db/db vs wt mice within the male DBA/2J cohort ranging 253 
from 32- to 44-fold compared with 16- to 18-fold in the BLKS/J2 cohort. Urinary concentrations of 254 
albumin were also significantly higher in DBA/2J vs BLKS/J db/db males (P<0.01, Fig. 6C). 255 
Furthermore, the urinary creatinine concentrations were similar in db/db mice between strains, 256 
but significantly higher in BLKS/J vs DBA/2J wt mice (P<0.05, Fig. 6D). Finally, we assessed serum 257 
creatinine levels in a subset of DBA2J and BLKS/J mice at 12 weeks of age. This revealed no 258 
significant differences between db/db and their wild-type controls on either the DBA2J or BLKS/J 259 
backgrounds (Fig. 6E). 260 
The impact of genetic background on kidney weights and glomerular histological changes 261 
was also investigated. Firstly, relative kidney weight was significantly reduced in db/db vs wt 262 
BLKS/J mice (P<0.001, Table 3), while no significant differences in kidney weight were observed 263 
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between DBA/2J groups. Between strains, relative, but not absolute kidney weight was 264 
significantly higher in db/db DBA/2J vs BLKS/J mice (P<0.01, Table 3). 265 
Semi-quantitative histological evaluation showed increased GS in db/db vs wt mice by 12 266 
weeks of age in both strains (both P<0.001, Table 3), whereas the glomerular area was significantly 267 
enlarged in db/db vs wt in the DBA/2J strain (P<0.001, Table 3), but not BLKS/J. Finally, comparison 268 
of the DBA/2J and BLKS/J cohorts showed no significant effect of genetic background on GS and 269 
glomerular area in db/db and in wt mice.     270 
The effect of background strain on ultrastructural changes in glomeruli was evaluated by 271 
TEM and representative micrographs presented in Fig. 5A. In both strains, podocyte foot process 272 
width and GBM thickness was significantly increased in db/db vs wt mice (for both strains P<0.05, 273 
Fig. 5B and P<0.001, Fig. 5C, respectively). Furthermore, the width of foot processes was 274 
significantly higher in db/db BLKS/J vs DBA/2J mice (P<0.001, Fig.5B), while the GBM thickness did 275 
not differ between strains (Fig. 5C). No significant differences were observed between DBA/2J and 276 
BLKS/J wild-type mice. 277 
 278 
Discussion 279 
DN research and drug development is challenged by the shortcomings of current animal models. 280 
Considerable resources are therefore invested in the development of novel animal models that 281 
reproduce features of human disease. In this study, we followed the advancement of early DN in 282 
the db/db DBA/2J mouse and found that it developed robust albuminuria starting between 6 and 283 
8 weeks of age that correlated closely with systemic insulin resistance, body weight and blood 284 
glucose levels. We then compared male db/db DBA/2J mice with an age-matched cohort of male 285 
db/db BLKS/J mice, which is the major strain used in type-2 DN research, and found a significant 286 
effect of genetic background on the severity of urinary albumin excretion despite similar levels of 287 
hyperglycemia and systemic insulin resistance in both strains. This study underlines the impact of 288 
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genetic background on the propensity to renal injury in mouse models of diabetes and DN, and 289 
confirms the susceptibility of the DBA/2J strain to albuminuric kidney disease.  290 
Like BLKS/J, the DBA/2J strain is susceptible to the diabetogenic actions of the db allele. This 291 
causes these mouse strains to develop overt type-2 diabetes with pancreatic exhaustion, beta-cell 292 
depletion and insulinopenia after a preceding period of systemic insulin resistance leading to 293 
pancreatic hypertrophy and hyperinsulinemia as in human type-2 diabetes patients. The duration 294 
of the gradual transition from systemic insulin resistance to overt diabetes-2 depend varies 295 
between mouse strains and gender (20). Here, we observed an early onset of hyperglycemia and 296 
systemic insulin resistance in female and male db/db DBA/2J mice at 6 and 8 weeks of age, 297 
respectively. As seen in various mouse models of diabetes (10, 20), males displayed accelerated 298 
advancement of the diabetic phenotype relative to females and developed severe hyperglycemia 299 
and insulinopenia resulting in weight loss starting at 10 weeks of age possibly due to glycosuria. In 300 
contrast, female db/db DBA/2J mice displayed sustained hyperinsulinemia by 12 weeks of age 301 
explaining the stabilized, although elevated, blood glucose levels through 8-12 weeks of age. 302 
Furthermore, the metabolic manifestations of the db allele - in terms of hyperglycemia and 303 
systemic insulin resistance - were similar in the male db/db DBA/2J and BLKS/J cohorts by 12 304 
weeks of age. These data are consistent with previous studies by Leiter et al. who studied the 305 
metabolic parameters in DBA/2J and BLKS/J db/db mice and classified them “diabetes prone” in 306 
contrast to  “diabetes-resistant” C57BL/6 mice (20).  307 
In human patients as well as in animal models, albuminuria is used as the hallmark 308 
biomarker of DN. In mice, it has been shown that genetic factors modulate the levels of 309 
albuminuria in models of type-1 diabetes including the STZ-induced and Akita models (14, 29, 34) 310 
as well as in type-2 diabetes in the db/db model (31). In this study, we observed robust 311 
albuminuria by 8 weeks of age in both female and male db/db DBA/2J mice. Furthermore, we saw 312 
a development in albuminuria with ACR fold changes in db/db relative to age- and gender-313 
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matched controls resulting in a 56-fold increase in females and a 44-fold increase in males by 12 314 
weeks of age. As far as we are aware this is the first study that has examined the development of 315 
albuminuria in the db/db model on a DBA2J background. We decided to compare this genetic 316 
strain to the most widely studied strain that develops early DN, BLKS/J. Importantly we studied 317 
both strains of mice in the same environment, using the same feeding regimen, and collected all 318 
samples in a similar manner. Despite these measures, the different vendors of the mouse strains 319 
cannot be excluded as a confounding factor. Our head-to-head strain comparison showed 320 
significantly higher levels of urinary albumin excretion in male db/db DBA/2J mice compared with 321 
db/db BLKS/J mice as assessed by urinary ACR. This feature was mainly driven by an increase in 322 
crude urinary albumin excretion rather than a reduction in urinary creatinine levels. Furthermore, 323 
although we didn’t measure formal glomerular filtration rates in our mice we did measure serum 324 
creatinine levels in a subset of mice which were not significantly different. This suggests that there 325 
wasn’t a major difference in the level of hyperfiltration between DBA2J and BLKS mice. GFRs have 326 
not been previously assessed in db/db DBA2J mice however they have been performed in BLKS 327 
db/db and wild-type mice. These studies have revealed either no difference in the level of GFR 328 
between these groups at 24 weeks (35) or a small increase in the db/db mice at 18 weeks (4). In 329 
the future it will be interesting to rigorously assess the progression of hyperfiltration in the db/db 330 
DBA2J model using formal GFR assessment but this wasn’t the focus of this study. 331 
Alongside albuminuria, features of DN in the db/db mouse include histopathological findings 332 
such as glomerulosclerosis and glomerular enlargement as well as ultrastructural changes 333 
including foot process effacement and GBM thickening. Our data showed that glomerulosclerosis 334 
was increased in db/db compared to wild-type DBA/2J mice by 8-weeks of age and glomerular 335 
enlargement was detectable by 12 weeks of age. Compared with the db/db BLKS/J cohort, we 336 
detected no differences in these features in the db/db DBA2J males. It has previously been 337 
described in mouse models of DN that increased levels of urinary albumin excretion do not 338 
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translate into exacerbation of histopathological changes (14, 28). This may simply be due to the 339 
superior sensitivity of the urinary albumin excretion relative to semi-quantitative histological 340 
analysis in detecting renal damage. Furthermore, the ultrastructural changes of the glomeruli 341 
described here do not explain the observed increase in ACR in db/db DBA/2J mice compared to 342 
the BLKS/J strain. Together, our data suggest that the increased susceptibility to albuminuria of 343 
the DBA/2J mouse may be caused by underlying genetic makeup leading to differences in the 344 
molecular susceptibility to albuminuric kidney disease. 345 
We characterized the development of metabolic parameters during the transition from 346 
systemic insulin sensitivity to resistance, and through to overt diabetes. We observed positive 347 
correlations between ACR and systemic insulin resistance as well as glomerulosclerosis scores in 348 
the db/db DBA/2J mouse model. Clinically, these findings are potentially important as they mimic 349 
the association between microalbuminuria and insulin resistance observed in non-diabetic 350 
metabolic syndrome patients (24, 27) and in diabetic subjects (9, 15). Thus, our findings support 351 
the applicability of the db/db DBA/2J mouse to study these early stages of insulin resistant 352 
glomerulopathies and DN in order to decipher the pathophysiological events that may precede 353 
and accelerate the progression to late stage DN. 354 
Together with a growing amount of experimental data from mouse models of diabetes (13, 355 
14) and models of diet-induced obesity (32), the present study confirms the notion that DBA/2J 356 
display enhanced sensitivity to metabolically-induced albuminuria kidney disease. When 357 
compared to BLKS/J mice, at its onset, systemic insulin resistance was less in the db/db DBA/2J 358 
mice, but they exhibited significantly more albuminuria. This suggests that the inherent cellular 359 
insulin resistance in DBA/2J mice must be greater than that in the BLKS/J strain, which has 360 
previously been described by others (3). Studies have been conducted to identify genetic 361 
contributors to diabetes susceptibility in the db/db mouse model (8), but fail to distinguish 362 
diabetes and DN-susceptibility loci. Further genetic analyses are therefore required to identify 363 
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genes that are differentially expressed between the diabetes-prone DBA/2J and BLKS/J strains and 364 
that may explain the molecular difference underlying the present observations as previously 365 
achieved in a comparison between the DBA/2J and C57BL/6 strains (29). Finally, as the DBA/2J is a 366 
pure inbred strain, it is attractive as it will be possible to generate db/db mice carrying specific 367 
transgenes that can be back-crossed onto this albuminuric susceptible genetic background to 368 
decipher the molecular mechanisms of this underlying insulin resistance and the influence on the 369 
establishment and development of DN in the kidney, glomerulus and even in individual cell 370 
populations such as the podocytes in this kidney disease-prone strain.  371 
In summary, we have demonstrated that the db/db DBA/2J mouse develops robust 372 
albuminuria by 8 weeks of age alongside histopathological features of early DN including 373 
glomerulosclerosis and glomerular enlargement by 8 and 12 weeks of age, respectively. This is 374 
closely linked to systemic insulin resistance. The observed correlations between albuminuria and 375 
metabolic parameters support the applicability of this model as a clinically relevant model for 376 
biomedical research and drug development in insulin resistant states, diabetes and early DN. 377 
Further studies are required to explore whether the DBA/2J background also display an enhanced 378 
acceleration of the progression to late stage DN in the db/db mouse model of diabetes.  379 
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Figure Legends 490 
Figure 1 | Metabolic phenotype of the db/db DBA/2J mouse. A | Body weight and B | non-fasted 491 
blood glucose in female and male db/db DBA/2J mice and wt controls from 6-12 weeks of age. 492 
Data are mean ± SEM, n=7-12. *P<0.05, **P<0.01, ***P<0.001: Within same gender and age, 493 
groups are significantly different. C | Plasma insulin in female and male db/db DBA/2J mice and wt 494 
controls at 12 weeks of age. Data are mean ± SEM, n=3-5. ***P<0.001: Within same gender, 495 
groups are significantly different.  496 
 497 
Figure 2 | Systemic insulin resistance in the db/db DBA/2J mouse. Systemic insulin resistance as 498 
assessed by Insulin Tolerance Tests (ITT) in female and male db/db and wt DBA/2J mice at 6, 8 and 499 
12 weeks of age. A, C | Mice were fasted for 6 h and blood glucose measured before and after 500 
intraperitoneal administration of insulin (0.20 IU/kg in females, 0.50 IU/kg in males). B, D | 501 
Systemic insulin resistance quantified as Area under the curve (AUC) from ITT curves in females 502 
and males, respectively. Data are mean ± SEM, n = 3-11. **P<0.01, ***P<0.001: At individual time-503 
points, groups are significantly different.    504 
 505 
Figure 3 | Urinary albumin excretion in the db/db DBA/2J mouse. Development of urinary 506 
albumin excretion quantified as the albumin-to-creatinine ratio (ACR) in spot urine samples from A 507 
| female and B | male db/db DBA/2J mice and wt controls through 6-12 weeks of age. Dots 508 
represent individual animals and lines indicate medians, n = 4-12. **P<0.01, ***P<0.001: At 509 
individual time-points, groups are significantly different. C | ACR fold change in db/db relative to 510 
gender and age-matched wt controls. Bars are mean ± SEM, n = 4-12. ***P<0.001: Independent of 511 
gender, significant difference between time-points. D-F | Correlations between urinary ACR and D 512 
| body weight, E | non-fasted blood glucose and F | systemic insulin resistance in the db/db 513 
DBA/2J mouse. Dots represent individual animals and lines are fitted by linear regression within 514 
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each gender (  females,  males). All correlations are statistical significant (P<0.001, R2 are 515 
given in individual graphs), n = 34-71.   516 
 517 
Figure 4 | Renal histopathology in the db/db DBA/2J mouse. A | Representative micrographs of 518 
renal cortex and glomeruli from db/db and wt DBA/2J mice by 12 weeks of age stained with 519 
Periodic acid-Schiff and Masson’s trichrome as well as nephrin and collagen IV antibodies. All scale 520 
bars are 50 µm. B | Distribution of glomerulosclerosis scores (GS) in db/db DBA/2J mice by 8 (n = 521 
2) and 12 weeks of age (n = 4) compared with wt DBA/2J controls (n = 6, compiled across 8-12 522 
weeks of age). C | Mean GS in db/db DBA/2J and wt mice at 8 and 12 weeks of age. Bars are mean 523 
± SEM, n = 2-4. ***P<0.001: At individual time-points, groups are significantly different. D | 524 
Correlation between urinary ACR and mean GS. Dots represent individual animals (n = 16), the 525 
correlation was fitted by linear regression (P<0.001, R2 = 0.7686) and the dotted line indicate the 526 
95% confidence interval.   527 
 528 
Figure 5 | Glomerular ultrastructure in the db/db mouse model. The ultrastructural changes of 529 
glomeruli were evaluated by transmission electron microscopy (TEM) at 12 weeks of age. A | 530 
Representative TEM micrographs of podocyte foot processes and the glomerular basement 531 
membrane (GBM) in 12 week old wt and db/db DBA/2J and BLKS/J mice. Glomeruli were 532 
systematically evaluated to quantify B | the podocyte foot process width and C | the GBM 533 
thickness in wt and db/db both within and between mouse strains. Bars are means ± SEM. 534 
*P<0.05, ***P<0.001: Groups are significantly different.  535 
 536 
Figure 6 | Modulation of urinary albumin excretion by genetic background in the db/db mouse 537 
model. The urinary albumin excretion was evaluated in spot urine samples from male db/db and 538 
wt DBA/2J and BLKS/J mice through 8-12 weeks of age. A | Evaluation by SDS-PAGE (5 µl urine per 539 
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lane) followed by comassie stain using BSA (~66kDa) as positive control. Urinary B | ACR and C | 540 
albumin concentrations in spot urine samples. Dots represent individual animals (n = 4-12) and 541 
lines indicate medians. D | Urinary creatinine concentrations in spot urine samples. Bars are mean 542 
± SEM, n = 4-12. *P<0.05, **P<0.01: Within same group, strains are significantly different. E | Dot 543 
blot of serum creatinine measured in 12 week old mice. Analyzed with a one-way ANOVA revealed 544 
no significant difference between any groups. N=3-6 for each group.  545 
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Tables 546 
Table 1 | DBA/2J breeding outcome 547 
  Female Male Total 
Litters  - - 12 
Mice per litter (mean)  2.7 2.8 5.5 
Gender (fraction)  0.49 0.51 1.00 
Genotype (fraction) 
db/db 0.32 0.41 0.36 
db/wt 0.52 0.44 0.48 
wt/wt 0.16 0.15 0.16 
   28 
Table 2 | Metabolic parameters in the DBA/2J and BLKS/J db/db mouse models 548 
 Body weight  (g)  
Non-fasted blood glucose  
(mM)  
Area under Curve  
(mM*min) 
 wt db/db  wt db/db  wt db/db 
 8 weeks 
DBA/2J 24.0±1.5 33.1±0.7*‡  7.88±0.39 16.94±2.09*‡  450.9±64.2 1007.3±87.4*‡ 
BLKS/J 25.7±0.5 39.7±0.8*  6.95±0.29 26.05±1.52*  372.4±20.2 2264.8±147.5* 
 10 weeks 
DBA/2J 25.5±1.6 34.9±0.7*‡  7.75±0.45 27.31±1.19*  ND ND 
BLKS/J 27.8±0.8 42.2±0.9*  7.30±0.32 29.9±1.21*  ND ND 
 12 weeks 
DBA/2J 27.3±1.5 33.0±1.1*‡  7.77±0.32 31.01±0.86*  402.3±42.8 1836.8±326.1*† 
BLKS/J 28.7±0.8 42.1±1.2*  7.10±0.21 28.63±1.21*  405.9±15.3 2530.5±121.0* 
Data are mean ± SEM, n = 3-12 for DBA/2J mice, n = 6 for BLKS/J mice. *P<0.001: Within same strain and age, groups 549 
are significantly different. †P<0.05, ‡P<0.001: Within same group and age, strains are significantly different. ND: Not 550 
determined.  551 
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Table 3 | Kidney weights and glomerular structure in the DBA/2J and BLKS/J db/db mouse models 552 
 Absolute weight  (g)  
Relative weight 
(mg kidney/g body weight)  Mean glomerulosclerosis score  
Glomerular area 
(µm2) 
 wt db/db  wt db/db  wt db/db  wt db/db 
DBA/2J 0.489±0.034† 0.524±0.068  18.42±0.71‡ 16.79±3.17‡  0.21±0.10 1.35±0.13*  3878±86 4653±238* 
BLKS/J 0.379±0.016 0.410±0.024  13.77±0.51 9.78±0.63*  0.45±0.13 1.47±0.10*  4274±197 4765±220 
Data are mean ± SEM, n = 4-6. *P<0.001: Within same strain, signiﬁcant diﬀerence between groups. †P<0.05, ‡P<0.01: 553 
Within same group, strains are significantly different. 554 
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